Recent findings in bipolar disorder described by researchers from Maastricht University
2009 JUL 27 - (NewsRx.com) -- "It has been suggested that dopamine dysfunction may play a role in bipolar disorder (BD). An indirect approach to examine this issue was developed, focusing on associations between dopamine proxy measures observed in BD (dopamine-related clinical traits using tardive movement syndromes as dopamine proxy measure of reference)," researchers in Maastricht, Netherlands report. "3459 eligible bipolar patients were enrolled in an observational study. Incidence rates of tardive movement syndromes (tardive dyskinesia and tardive dystonia; TDD) were examined. A priori hypothesized associations between incident TDD and other dopamine proxies (e.g. prolactin-related adverse effects, bipolar symptoms) were tested over a 2 year follow-up period. The incidence rate of tardive syndromes was 4.1%. Incident TDD was independently associated not only with use of antipsychotics, but also with more severe bipolar symptoms, other extrapyramidal symptoms and prolactin-related adverse effects of medication," wrote I. Vanrossum and colleagues, Maastricht University. The researchers concluded: "Apart from the well-known association with antipsychotics, development of TDD was associated with various other dopamine proxy measures, indirectly supporting the notion of generalised dopamine dysregulation in BD.." Vanrossum and colleagues published their study in BMC Psychiatry (Bipolar disorder and dopamine dysfunction: an indirect approach focusing on tardive movement syndromes in a naturalistic setting. BMC Psychiatry, 2009;9():16). For additional information, contact I. Vanrossum, Maastricht University, Dept. of Psychiatry & Neuropsychol, Maastricht, Netherlands. Publisher contact information for the journal BMC Psychiatry is: Biomedical Central Ltd., Current Science Group, Middlesex House, 34-42 Cleveland St., London W1T 4LB, England. Keywords: Netherlands, Maastricht, Bipolar Disorder, Dopamine Hydrochloride, Drugs, Dystonia, Manic-Depressive Illness, Neurology, Pharmaceuticals, Psychiatry, Tardive Dyskinesia, Therapy, Treatment, Maastricht University. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
